INVA
Innoviva, Inc.Company with tickers: INVA
CIK
1080014
CUSIP
45781M101
Shares Outstanding
73,808,749
Website
https://www.inva.com
13F Activity (30d)
16 filings
13 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $1,100,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Revenue (ASC 606) | $97,994,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Cost of Revenue | — | ||||
| Gross Profit | $75,833,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Expenses | $37,679,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Research & Development | $5,241,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | $38,154,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Net Income | — | ||||
| EPS (Basic) | $2.52 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $2.22 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|
| Royalty | $326,794,000 | $391,866,000 | $311,645,000 | $238,846,000 | $241,733,000 | $236,479,000 |
| Product | — | $0 | $19,694,000 | $60,617,000 | $97,492,000 | $172,130,000 |
| Xacduro | — | — | $0 | $2,003,000 | $21,070,000 | $74,393,000 |
| Giapreza | — | — | $14,214,000 | $41,294,000 | $55,037,000 | $73,611,000 |
| Xerava | — | — | $5,480,000 | $17,320,000 | $21,385,000 | $23,516,000 |
| License And Other Revenue | — | — | $0 | $11,000,000 | $19,486,000 | $2,719,000 |
| ZEVTERA | — | — | — | $0 | $0 | $610,000 |
| Collaborative Arrangements | $10,000,000 | — | — | — | — | — |
| License Revenue | — | $0 | $0 | $11,000,000 | — | — |